

Reviewer 1

1. "in vivo""in vitro" should be italic.

Answer: Amended as suggested

2. "neuroendocrine lung tumors" and "lung neuroendocrine tumors" have been both used in the manuscript, please be consistent.

Answer: Both terms are turned into "neuroendocrine lung tumors".

3. Although the authors mentioned "This review would provide the latest updated data from the literature", however, no reference published in 2022, 2020, 2019, 2017 was cited, and only 2 references in 2021, 1 reference in 2018, 1 reference in 2016 was cited. Which means most of the references are not updated, which makes the review not written with newly results and progress.

Answer: Using the keywords "neuroendocrine lung tumor", "angiogenesis", "oxidative stress", "neuroendocrine serum markers" and "neuroendocrine tissue markers" we performed a literature research based on the most important medical research databases (RCA, Pubmed). We have obtained the following results about the articles published in the last 5 years (only article PDFs available).

- a) Neuroendocrine lung tumors: 1 article;
1 article (2018)
- b) Angiogenesis in respiratory system: 36 articles.
5 articles (2022), 15 articles (2021), 20 articles (2020), 9 articles (2019), 11 articles (2018)
- c) Oxidative stress in respiratory system: 60 articles.
5 articles (2022), 15 articles (2021), 20 articles (2020), 9 articles (2019), 11 articles (2018)
- d) Neuroendocrine serum markers: no article found.
- e) Neuroendocrine tissue markers: no article found.
- f) Angiogenesis and oxidative stress in neuroendocrine lung tumors: no article found.

In the Abstract and Core tip section of our minireview we have stated "This review would provide the latest updated data from the literature on angiogenesis and oxidative stress in neuroendocrine lung tumors."

As reported above no paper are available, neither recently nor in the past, on this very specific topic. So, we cited just only the well-known and most-cited publications on the general aspect of angiogenesis, oxidative stress and neuroendocrine lung tumors. Furthermore, we updated and increased the References section.

4. ref 47 and 32 are same.

Answer: Thanks for pointing out the mistake. The references' number has been corrected and updated.

5. updated clinical application targeting angiogenesis and oxidative stress in lung NET need to be added and discussed, and a table summarizing the key information is recommended. demonstrated the content focusing on the lung NET.

Answer: After a careful search on the main medical research databases (e.g., PMI, Reference Citation Analysis etc.) in the last 10 years no paper has been published on the applications of targeted therapy against angiogenesis and oxidative stress in neuroendocrine lung tumors. Our minireview represents a new starting

point for the subsequent publication of the innovative data on oxidative stress and angiogenesis in lung neuroendocrine tumors already presented at the last World conference on lung cancer (WCLC-2022) and the European Society of Thoracic Surgeon congress (ESTS-2022).

6. Both figure and table are not demonstrated the content focusing on the lung NET.

Answer: Due to the lack of results and progresses on the angiogenesis and oxidative stress processes in neuroendocrine lung tumors both figure and table are referred only to the general aspects of tumor angiogenesis and oxidative stress.

Reviewer #2:

This review intend to describe the angiogenesis and oxidative stress involvement in lung neuroendocrine tumors. This topic could contribute to the research as well as clinical community if the review has been focused to deepen the understanding in angiogenesis in this kind of tumors. It is notable that the manuscript uploaded is not the final version (there are still tracked corrections).

1. The title is not attractive; it must encourage the principal findings summarized in the conclusions.

Answer: Thank you for your suggestion. Now, we modified title of review.

2. In the Introduction, I suggest to focus on the subject want to be described. For example, somatostatin in the introduction must be related to pathological angiogenesis.

Answer: we amended as suggested. (see page 6-7, lines 190-200)

3.The paragraph related to angiogenesis must be focused on pathological angiogenesis in neoplasms. Moreover, when describing the genetic factors involved in oxidative stress or angiogenesis, the authors mix between proteins or transcription factors and genetic mutations. I suggest to re-write the review and first, to assort the different topics in the manuscript. Then, to make a table with the markers and the correlation between them to be useful in the prognosis and new therapies for lung neoplasm's. There are many language mistakes to be revised.

Answer: Thank you. We added a table about the specific target of oxidative stress in tumor growth. (see Table 2)